amoxapine has been researched along with Enterocolitis, Pseudomembranous in 1 studies
Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.
amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.
Enterocolitis, Pseudomembranous: An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A total of 17 prioritized drugs, based on efficacy in in vitro screens, were chosen for further evaluation in a murine model of pneumonic plague to delineate if in vitro efficacy could be translated in vivo Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect on Y." | 3.83 | New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. ( Andersson, JA; Chauhan, S; Chopra, AK; Dann, SM; Fitts, EC; Kirtley, ML; Motin, VL; Peniche, AG; Ponnusamy, D; Rosenzweig, JA; Sha, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, JA | 1 |
| Fitts, EC | 1 |
| Kirtley, ML | 1 |
| Ponnusamy, D | 1 |
| Peniche, AG | 1 |
| Dann, SM | 1 |
| Motin, VL | 1 |
| Chauhan, S | 1 |
| Rosenzweig, JA | 1 |
| Sha, J | 1 |
| Chopra, AK | 1 |
1 other study available for amoxapine and Enterocolitis, Pseudomembranous
| Article | Year |
|---|---|
New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.
Topics: Amoxapine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Clostridioides difficile | 2016 |